Seth Meyers checks in on 'pharma bro' Martin Shkreli, finds he's just the tip of a price-gouging iceberg


Martin Shkreli, the widely despised former CEO of Turing Pharmaceuticals, infamous for raising the price of a life-saving drug by 5,000 percent, was called to testify before Congress last week. But instead of answering questions, Seth Meyers said on Tuesday's Late Night, "he spent the time doing what he does best: looking like a real slappable prick." Meyers illustrated his point with some footage of Shkreli invoking his Fifth Amendment right instead of answering even the most mundane questions.
As fun as it is to make fun of Shkreli, though, he's "not alone," Meyers said. "He's just doing what a lot of pharmaceutical companies already do, except he's being loud and conniving about it while they're being secretive and conniving about it." In fact, Shkreli is "just a convenient, deserving scapegoat" for the price-gouging of Americans by the drug industry, Meyers said, aided by Congress' decision to prevent the U.S. government from negotiating the price of drugs, like almost every other country does. Case in point, a company called Valeant bought two heart drugs just last year and immediately raised the price 525 percent and 212 percent, Meyers said, but "Valeant didn't cause nearly as much outrage as Shkreli did because they don't have a smug, irritating face; they have a soothing logo." Watch Meyers' "closer look" at Shkreli and the unsavory behavior he exposed below. Peter Weber
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Peter has worked as a news and culture writer and editor at The Week since the site's launch in 2008. He covers politics, world affairs, religion and cultural currents. His journalism career began as a copy editor at a financial newswire and has included editorial positions at The New York Times Magazine, Facts on File, and Oregon State University.
-
Taking aim at Venezuela’s autocrat
Feature The Trump administration is ramping up military pressure on Nicolás Maduro. Is he a threat to the U.S.?
-
Comey indictment: Is the justice system broken?
Feature U.S. attorney Lindsey Halligan has indicted former FBI Director James Comey on charges of lying and obstructing Congress
-
Government shuts down amid partisan deadlock
Feature As Democrats and Republicans clash over health care and spending, the shutdown leaves 750,000 federal workers in limbo
-
Electronic Arts to go private in record $55B deal
speed read The video game giant is behind ‘The Sims’ and ‘Madden NFL’
-
New York court tosses Trump's $500M fraud fine
Speed Read A divided appeals court threw out a hefty penalty against President Trump for fraudulently inflating his wealth
-
Trump said to seek government stake in Intel
Speed Read The president and Intel CEO Lip-Bu Tan reportedly discussed the proposal at a recent meeting
-
US to take 15% cut of AI chip sales to China
Speed Read Nvidia and AMD will pay the Trump administration 15% of their revenue from selling artificial intelligence chips to China
-
NFL gets ESPN stake in deal with Disney
Speed Read The deal gives the NFL a 10% stake in Disney's ESPN sports empire and gives ESPN ownership of NFL Network
-
Samsung to make Tesla chips in $16.5B deal
Speed Read Tesla has signed a deal to get its next-generation chips from Samsung
-
FCC greenlights $8B Paramount-Skydance merger
Speed Read The Federal Communications Commission will allow Paramount to merge with the Hollywood studio Skydance
-
Tesla reports plummeting profits
Speed Read The company may soon face more problems with the expiration of federal electric vehicle tax credits